KW-6356
KW-6356 is a pharmaceutical drug with 7 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
2
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
7 of 7 finished
0.0%
0 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356
Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite
A Through QT/QTc Study of KW-6356
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin
Clinical Trials (7)
Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356
Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite
A Through QT/QTc Study of KW-6356
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin
A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin
A Study of KW-6356 in Subjects With Early Parkinson's Disease
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7